Promising new combo aims to outperform standard chemo for tough lung cancer
NCT ID NCT07464327
First seen Mar 13, 2026 · Last updated Jun 12, 2026 · Updated 11 times
Summary
This phase 3 study tests whether a new drug (HS-20093) combined with an immunotherapy (adebrelimab) works better than the standard chemo (docetaxel) for people with advanced non-squamous non-small cell lung cancer that has no targetable genetic changes. About 450 adults who have already had treatment will be randomly assigned to one of the two groups. The main goals are to see if the combo delays cancer growth and helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.